Literature DB >> 19543316

SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.

S Haan1, S Wüller, J Kaczor, C Rolvering, T Nöcker, I Behrmann, C Haan.   

Abstract

Recently, mutations in the gene of Janus kinase 2 (Jak2) were discovered in patients suffering from chronic myeloproliferative disorders (MPD) and leukemia. As suppressors of cytokine signaling (SOCS) proteins are potent feedback inhibitors of Jak-mediated signaling, we investigated their role in signal transduction through constitutively active Jak2 mutants. We selected two mutants, Jak2-V617F and Jak2-K539L, found in patients with MPDs and Jak2-T875N identified in acute megakaryoblastic leukemia. We found SOCS family members to be induced through Jak2-V617F in human leukemia cell lines expressing the mutant allele and in stable HEK transfectants inducibly expressing constitutively active Jak2 mutants. SOCS proteins were recruited to the membrane and bound to the constitutively active Jaks. In contrast to wild-type Jak2, the mutant proteins were constitutively ubiquitinated and degraded through the proteasome. Taken together, we show a SOCS-mediated downregulation of the constitutively active, disease-associated mutant Jak2 proteins. Furthermore, a threshold level of mutant Jak expression has to be overcome to allow full cytokine-independent constitutive activation of signaling proteins, which may explain progression to homozygocity in MPDs as well as gene amplification in severe phenotypes and leukemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19543316     DOI: 10.1038/onc.2009.155

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

Review 2.  Erythropoietin receptor response circuits.

Authors:  Don M Wojchowski; Pradeep Sathyanarayana; Arvind Dev
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

Review 3.  Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Investig Drugs       Date:  2016-10-31       Impact factor: 6.206

4.  Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.

Authors:  Leila N Varghese; Daniela Ungureanu; Nicholas P D Liau; Samuel N Young; Artem Laktyushin; Henrik Hammaren; Isabelle S Lucet; Nicos A Nicola; Olli Silvennoinen; Jeffrey J Babon; James M Murphy
Journal:  Biochem J       Date:  2014-03-01       Impact factor: 3.857

Review 5.  Regulation and function of signal transducer and activator of transcription 3.

Authors:  Qian-Rong Qi; Zeng-Ming Yang
Journal:  World J Biol Chem       Date:  2014-05-26

6.  Differential biological activity of disease-associated JAK2 mutants.

Authors:  Haiying Zou; Dongqing Yan; Golam Mohi
Journal:  FEBS Lett       Date:  2011-03-04       Impact factor: 4.124

Review 7.  Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Authors:  Sara C Meyer; Ross L Levine
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

8.  A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Authors:  Kristine L Stump; Lily D Lu; Pawel Dobrzanski; Cynthia Serdikoff; Diane E Gingrich; Ben J Dugan; Thelma S Angeles; Mark S Albom; Mark A Ator; Bruce D Dorsey; Bruce A Ruggeri; Matthew M Seavey
Journal:  Arthritis Res Ther       Date:  2011-04-21       Impact factor: 5.156

9.  DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β.

Authors:  Toshikage Nagao; Gaku Oshikawa; Nan Wu; Tetsuya Kurosu; Osamu Miura
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

10.  Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.

Authors:  Michael R Marit; Manprit Chohan; Natasha Matthew; Kai Huang; Douglas A Kuntz; David R Rose; Dwayne L Barber
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.